Quiet, don't jinx it. I've got a full position.
Hopefully shorts are using this opportunity to cover.
Time to get this show on the road. If Sanofi isn't going to act, the rest of us can.
Sam's list is NOT all-inclusive as I understand it, so the 90 are not likely writing all of the 600 prescriptions. From what I know, the list is mostly comprised of doctors' names provided to Sam by those who are in contact with him either personally or via his blog, Twitter and YMB. There may be additional sources but I am not aware of them. You might want to contact Sam directly to clarify.
Longs on this board "hyped" pre-AdCom (said Afrezza would pass), hyped pre-FDA approval (said Afrezza would be approved), hyped pre-Sanofi partnership (deduced who would be the partner - I was one of the early ones), and hyped product performance (diabetics are getting unheard of results). Tell me where we went wrong. Your football game is in the pre-season now but ultimately Mannkind will win the Super Bowl (that's is now my most recent hype). Off to the ignore bin.
Not saying the ads are having significant impact, but they are out there. Please be factual in your posts.
I will not read his articles and add to his income via clicks. I have seen enough of them to know that they contain little substance and that his opinions/conclusions have proven to be wrong time and time again. Note that once again a bear raid seems to have been triggered by his article. To me he is nothing but a dog whistle for shorts and in my opinion a participant in what I feel to be a grand theft from investors.
There are ads. There are reps. There are studies. Perhaps you can come up with better support for your position.
These are incredible results! Thanks for posting. I've been out of the country and haven't been able to keep up with all of the postings.
Look forward to hearing your feedback. Could you also tell us what other meds besides insulin you are on? Will be helpful to see what competitors will be getting hit by Afrezza. Thanks and the best of luck with Afrezza.
Olivier Brandicourt experienced the Exubera debacle at Pfizer. He will not make the same mistake twice with Afrezza. I have patience.